News - afatinib, Analgesia

Filter

Current filters:

afatinibAnalgesia

Popular Filters

Study: Half of veterans prescribed medical opioids continue to use them chronically

Study: Half of veterans prescribed medical opioids continue to use them chronically

07-03-2014

A study of nearly 1 million veterans who receive opioids to treat painful conditions found that more…

AnalgesiaHealthcarePharmaceuticalResearchUSA

FDA says Durect’s pain relief drug Posidur needs additional safety studies

FDA says Durect’s pain relief drug Posidur needs additional safety studies

13-02-2014

US drugmaker Durect Corp says that the US Food and Drug Administration has issued a Complete Response…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

Altus signs $4 million agreement with Zogenix to license Zohydro ER

04-11-2013

Altus Pharmaceuticals has entered into an agreement with Zogenix to develop abuse deterrent formulations…

AnalgesiaLicensingNorth AmericaPharmaceuticalZogenixZohydro

Orexo’s Zubsolv could take market share from Suboxone, report suggests

Orexo’s Zubsolv could take market share from Suboxone, report suggests

30-10-2013

Edison Equity Research analysts say that expected new clinical data from Swedish drug developer Orexo…

AnalgesiaFinancialMarkets & MarketingNorth AmericaOrexo ABPharmaceuticalReckitt BenckiserZubsolv

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

28-10-2013

Data from two pivotal large-scale Phase III registration studies with German independent drug major Boehringer…

afatinibBoehringer IngelheimGilotrifGiotrifOncologyPharmaceuticalResearch

Zogenix shares leap after FDA approval for Zohydro ER

Zogenix shares leap after FDA approval for Zohydro ER

28-10-2013

Shares of Zogenix rocketed on Friday after the US Food and Drug Administration approved Zohydro ER extended-release…

AnalgesiaNorth AmericaPharmaceuticalRegulationZogenixZohydro

FDA calls for reclassification of codeine combo medications to stricter schedules

FDA calls for reclassification of codeine combo medications to stricter schedules

25-10-2013

The US Food and Drug Administration has indicated that it wants to see the classification of codeine-containing…

AnalgesiaHydrocodone Bitartrate and AcetaminophenNorth AmericaPharmaceuticalRegulation

Pfizer to continue Remoxy pain relief development

Pfizer to continue Remoxy pain relief development

24-10-2013

US pharma giant Pfizer will continue the development program for Remoxy Extended-Release Capsules CII,…

AnalgesiaNorth AmericaPfizerPharmaceuticalRemoxyResearch

Iroko’s pain relief drug effective at low doses

Iroko’s pain relief drug effective at low doses

22-10-2013

Iroko Pharmaceuticals has announced that the US Food and Drug Administration has approved Zorvolex capsules…

AnalgesiaIrokoNorth AmericaPharmaceuticalRegulationZorvolex

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

21-10-2013

Pfizer has announced mixed results from two Phase IIIb studies of Lyrica capsules CV in patients with…

AnalgesiaLyricaNorth AmericaPfizerPharmaceuticalResearch

UK’s medicines watchdog recalls five Wockhardt medicines

UK’s medicines watchdog recalls five Wockhardt medicines

18-10-2013

The UK’s Medicines and Healthcare products Regulatory Agency has recalled five medicines made by Indian…

AnalgesiaDiabetesEuropeGliclazidePharmaceuticalProductionRegulationWockhardt

Boehringer’s cancer drug Giotrif gains European marketing authorization

Boehringer’s cancer drug Giotrif gains European marketing authorization

27-09-2013

Boehringer Ingelheim has been granted marketing authorization from the European Commission for Giotrif…

afatinibBoehringer IngelheimEuropeOncologyPharmaceutical

Germany's Bayer and Boehringer both get CHMP backing

29-07-2013

Among a string of positive recommendations revealed last Friday (July 26) by the European Medicines Agency's…

afatinibBayerBoehringer IngelheimEuropeEyleaGiotrifOncologyOphthalmicsPharmaceuticalRegulation

US FDA approves Boehringer Ingelheim's first cancer drug

15-07-2013

In what the family-owned German drug major Boehringer Ingelheim hopes is just the first drug to come…

afatinibBiotechnologyBoehringer IngelheimGilotrifNorth AmericaOncologyPharmaceuticalQiagenRegulation

Boehringer Ingelheim's afatinib NDA gets priority review in USA

16-01-2013

The US subsidiary of German independent drug major Boehringer Ingelheim revealed yesterday that the New…

afatinibBoehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationTomtovok

Analysts view Boehringer Ingelheim's first move into cancer drug market

11-10-2012

German family-owned drug major Boehringer Ingelheim last month announced the submission of a Marketing…

afatinibBoehringer IngelheimMarkets & MarketingnintedanibOncologyPharmaceuticalResearchvolasertib

Boehringer Ingelheim files first oncology compound, afatinib, for EU approval

21-09-2012

German family-owned drug major Boehringer Ingelheim said yesterday that it has submitted a Marketing…

afatinibBoehringer IngelheimEuropeOncologyPharmaceuticalRegulation

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

Back to top